Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | RAD52 | P43351 | 2/20 | 0.38 |
| ▸ | UHRF1 | Q96T88 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12794865 | 0.94 | KDM4E (0.44) | PDE5APDE4BKDM4EMAPTTP53 | |
| SCHEMBL982972 | 0.85 | PDE5A (0.39) | PDE5APDE4BKDM4EMAPTTP53 | |
| SCHEMBL4062151 | 0.79 | HSP90AA1 (0.48) | KDM4EMAPTTP53KMT2AMEN1 | |
| SCHEMBL985654 | 0.78 | KDM4E (0.42) | PDE5APDE4BKDM4EMAPTTP53 | |
| SCHEMBL4766455 | 0.75 | HSP90AA1 (0.46) | KDM4EMAPTTP53KMT2AMEN1 | |
| SCHEMBL986150 | 0.71 | DUT (0.38) | KDM4EMAPTATMKMT2AMEN1 | |
| SCHEMBL24789637 | 0.69 | MAPT (0.36) | KDM4EMAPTGAAPOLB | |
| SCHEMBL12794869 | 0.69 | KMT2A (0.35) | KDM4EMAPTKMT2AMEN1PKM | |
| SCHEMBL4104185 | 0.68 | NPC1 (0.50) | KDM4EMAPTTP53KMT2AMEN1 | |
| SCHEMBL30064908 | 0.68 | NPC1 (0.50) | KDM4EMAPTTP53KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247294-B1 | MACROLIDES FOR TREATING DISEASES MEDIATED THROUGH PDE INHIBITION | BASILEA PHARMACEUTICA AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| EP-2049556-B1 | NEW MACROLIDES USEFUL AGAINST INFLAMMATORY AND ALLERGIC DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-8445451-B2 | Macrolides and uses of macrolides | BASILEA PHARMACEUTICA AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-8173609-B2 | Macrolides useful against inflammatory and allergic diseases | BASILEA PHARMACEUTICA AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
| US-20100120706-A1 | Macrolides Useful Against Inflammatory and Allergic Diseases | BASILEA PHARMACEUTICA AG (CH) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120706-A1 | Macrolides Useful Against Inflammatory and Allergic Diseases | HRH4, HRH2, IL4 | PDE5A 4135/4885PDE4B 2041/4885KDM4E 3427/4885 |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | MRPS22, MRPS23, MRPL12 | PDE5A 3491/4885PDE4B 2412/4885KDM4E 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.